[go: up one dir, main page]

MX2018004282A - Nuevos procedimientos de fabricacion de barusiban y sus intermedios. - Google Patents

Nuevos procedimientos de fabricacion de barusiban y sus intermedios.

Info

Publication number
MX2018004282A
MX2018004282A MX2018004282A MX2018004282A MX2018004282A MX 2018004282 A MX2018004282 A MX 2018004282A MX 2018004282 A MX2018004282 A MX 2018004282A MX 2018004282 A MX2018004282 A MX 2018004282A MX 2018004282 A MX2018004282 A MX 2018004282A
Authority
MX
Mexico
Prior art keywords
barusiban
intermediates
new methods
making
specifically
Prior art date
Application number
MX2018004282A
Other languages
English (en)
Other versions
MX378320B (es
Inventor
Malik Leila
Wisniewski Kazimierz
Devin Chantal
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of MX2018004282A publication Critical patent/MX2018004282A/es
Publication of MX378320B publication Critical patent/MX378320B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06Antiabortive agents; Labour repressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K1/00General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/16Oxytocins; Vasopressins; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Analytical Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invención se refiere a nuevos procedimientos de péptidos en fase sólida de síntesis de análogos que presentan actividad antagonista de oxitocina, específicamente barusiban y sus intermedios. Específicamente, la presente invención se refiere a un procedimiento en fase sólida de preparación de un compuesto que tiene la fórmula c[AA1-AA6]-AA7-ol, en la que AA1 es ácido propiónico, AA2 es preferiblemente D-Trp, AA3 es Ile, AA4 es preferiblemente AlloIle, AA5 es Asn, AA6 es hCy, y AA7 es preferiblemente N-Me-Orn-ol, o una sal o solvato farmacéuticamente aceptable del mismo.
MX2018004282A 2015-10-06 2016-10-06 Nuevos procedimientos de fabricacion de barusiban y sus intermedios. MX378320B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15188529 2015-10-06
PCT/EP2016/073858 WO2017060339A1 (en) 2015-10-06 2016-10-06 New methods for making barusiban and its intermediates

Publications (2)

Publication Number Publication Date
MX2018004282A true MX2018004282A (es) 2018-08-09
MX378320B MX378320B (es) 2025-03-10

Family

ID=54288657

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004282A MX378320B (es) 2015-10-06 2016-10-06 Nuevos procedimientos de fabricacion de barusiban y sus intermedios.

Country Status (10)

Country Link
US (1) US20180282367A1 (es)
EP (1) EP3359557A1 (es)
JP (1) JP2018535946A (es)
KR (1) KR20180059549A (es)
CN (1) CN108290929A (es)
AU (1) AU2016335061B2 (es)
CA (1) CA3001057A1 (es)
MX (1) MX378320B (es)
RU (1) RU2726414C2 (es)
WO (1) WO2017060339A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7036791B2 (ja) 2016-07-21 2022-03-15 オブセヴァ エス.エー. 胚着床を促進し、流産を防ぐためのオキシトシンアンタゴニスト投与レジメン
CN110894212B (zh) * 2018-08-24 2021-06-04 翰宇药业(武汉)有限公司 一种合成依替巴肽硫醚的方法
JP7584201B2 (ja) 2019-09-03 2024-11-15 オブセヴァ エス.エー. 薬学的組成物
WO2021160597A1 (en) 2020-02-10 2021-08-19 ObsEva S.A. Biomarkers for oxytocin receptor antagonist therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE501678C2 (sv) 1993-07-13 1995-04-10 Ferring Bv Peptid med oxytocinantagonistaktivitet samt farmaceutisk komposition innehållande nämnda peptid
SE9604341D0 (sv) 1996-11-26 1996-11-26 Ferring Bv Hepta-peptide oxytocin analogue
ATE346084T1 (de) * 2002-02-27 2006-12-15 Ferring Bv Zwischenprodukte und verfahren zur herstellung von heptapeptid-oxytocinanaloga
TWI463990B (zh) * 2009-09-21 2014-12-11 Ferring Bv 催產素受體促進劑
CN102875650B (zh) 2012-09-26 2014-06-11 深圳翰宇药业股份有限公司 巴卢西班的制备方法

Also Published As

Publication number Publication date
RU2018116568A3 (es) 2020-01-27
WO2017060339A1 (en) 2017-04-13
AU2016335061B2 (en) 2021-02-25
RU2018116568A (ru) 2019-11-07
AU2016335061A1 (en) 2018-04-19
CN108290929A (zh) 2018-07-17
MX378320B (es) 2025-03-10
JP2018535946A (ja) 2018-12-06
CA3001057A1 (en) 2017-04-13
KR20180059549A (ko) 2018-06-04
EP3359557A1 (en) 2018-08-15
US20180282367A1 (en) 2018-10-04
RU2726414C2 (ru) 2020-07-14

Similar Documents

Publication Publication Date Title
EA201790407A1 (ru) Зонды для визуализации белка хантингтина
EA201892430A1 (ru) Синтез индазолов
CY1119731T1 (el) Διαδικασια για την παρασκευη παραγωγων χολικου οξεος
EA201791873A1 (ru) Полиморф ингибиторов syk
BR112016028773A2 (pt) processos para preparação de compostos antivirais
SMT202100647T1 (it) Composti del peptide tirosina tirosina ciclico accoppiato ad anticorpi come modulatori di recettori del neuropeptide y
EA201890093A1 (ru) Комбинированная терапия гемобластозов антителами к cd38 и ингибиторами сурвивина
EA201890899A1 (ru) Модуляторы фарнезоидного x-рецептора
MX362383B (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
EA201691541A1 (ru) Новые анти-baff антитела
EA201691031A1 (ru) Синтез макроциклического трипептида, ингибирующего hcv ns3
EA201790400A1 (ru) Зонды для визуализации белка хантингтина
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
EA201692548A1 (ru) Минеральные аминокислотные комплексы активных веществ
MX2018004282A (es) Nuevos procedimientos de fabricacion de barusiban y sus intermedios.
EA201691141A1 (ru) Соединения против ccr6
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
EA201790983A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201790432A1 (ru) Зонды для визуализации белка хантингтина
EA201790982A1 (ru) Синтез копанлисиба и его дигидрохлорида
EA201992421A1 (ru) Способ получения озанимода
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
CL2018002756A1 (es) Un proceso mejorado para la preparación de tartrato de butorfanol.
EA201891431A1 (ru) Способы получения замещенного 5,6-дигидро-6- фенилбензо[f]изохинолин-2-амина
PH12016500742A1 (en) Novel peptide having 4 linked ctl epitopes